Case ReportAcute Coronary Syndromes Complicating the First Infusion of Rituximab
References (14)
- et al.
IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
Blood
(1997) - et al.
Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)
Blood
(1999) - et al.
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
Blood
(2001) - et al.
Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study
Ann Oncol
(2002) - et al.
Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma
Blood
(2000) - et al.
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)
Blood
(2003) - et al.
New treatment options have changed the survival of patients with follicular lymphoma
J Clin Oncol
(2005)
Cited by (34)
Common Vascular Toxicities of Cancer Therapies
2019, Cardiology ClinicsCitation Excerpt :Furthermore, profound coronary vasospasm as seen with 5-FU, particularly with continuous infusion (less so with bolus infusion of 5-FU and capecitabine), can lead to ST segment elevation and, if prolonged, to MI, ventricular arrhythmias, such as ventricular tachycardia and fibrillation, and even sudden cardiac death.39–41 Profound and prolonged vasospasm is considered to also underlie ACS presentations with paclitaxel, gemcitabine, rituximab, and sorafenib.42–47 The level of suspicion for an acute thrombotic event should be high in patients who present with chest pain while on cisplatin (and especially in those on concomitant therapy with additional endothelial toxic drugs, such as vinca alkaloids, bleomycin, or gemcitabine).48,49
Cardiac Immunomodulation
2017, The Heart in Rheumatic, Autoimmune and Inflammatory Diseases: Pathophysiology, Clinical Aspects and Therapeutic ApproachesMyocardial Ischemia and Cancer Therapy
2017, Cardio-Oncology: Principles, Prevention and ManagementVascular Toxicities of Cancer Therapies
2016, Clinical Cardio-oncologyA systematic review of the use of rituximab as induction therapy in renal transplantation
2015, Transplantation ReviewsCitation Excerpt :6 of these deaths were due to cardiovascular events (myocardial infarction/cardiac arrest) and, given published evidence that B-lymphocytes may have an atheroprotective effect [38], the authors raise the possibility that rituximab therapy may have contributed to the excess cardiac mortality seen. There are a number of case reports and series describing cardiac morbidity related to rituximab treatment in the field of oncology [39,40] but evidence from larger studies and clinical trials has not demonstrated excess risk [41,42]. The findings of the studies which reported a high incidence of rejection using rituximab in CNI minimisation [31] and steroid avoidance [35] protocols should be interpreted with caution.
Myocardial infarction after rituximab infusion
2013, Neuromuscular DisordersCitation Excerpt :Cardiac dysrhythmia is a relatively frequently (8%) reported cardiovascular side-effect in lymphoma patients treated with rituximab [3]. Myocardial infarction after rituximab infusion is extremely rare and described in only a few (n = 4) cases [4,5]. Median age of these reported patients was 60 years, all having classical cardiovascular risk factors together with a lymphoproliferative disorder (which can also be considered as a vascular risk factor).
Electronic forwarding or copying is a violation of US and International Copyright Laws.
Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1557-9190, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.